Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

被引：31

作者：

LaCasce, Ann S. ^{[1
]}

Bociek, R. Gregory ^{[2
]}

Sawas, Ahmed ^{[3
]}

Caimi, Paolo ^{[4
]}

Agura, Edward ^{[5
]}

Matous, Jeffrey ^{[6
]}

Ansell, Stephen M. ^{[7
]}

Crosswell, Howland E. ^{[8
]}

Islas-Ohlmayer, Miguel ^{[9
]}

Behler, Caroline ^{[10
]}

Cheung, Eric ^{[11
]}

Forero-Torres, Andres ^{[12
,13
,15
]}

Vose, Julie ^{[2
]}

O'Connor, Owen A. ^{[3
]}

Josephson, Neil ^{[13
,15
]}

Wang, Yinghui ^{[13
]}

Advani, Ranjana ^{[14
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Nebraska Med Ctr, Omaha, NE USA

[3] Columbia Univ, Med Ctr, New York, NY USA

[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[5] Charles A Sammons Canc Ctr, Dallas, TX USA

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Mayo Clin, Rochester, MN USA

[8] St Francis Hosp, Greenville, SC USA

[9] Jewish Hosp Mercy Hlth, Cincinnati, OH USA

[10] Pacific Hematol Oncol Associates, San Francisco, CA USA

[11] Oncol Inst Hope & Innovat, Whittier, CA USA

[12] Univ Alabama Birmingham, Birmingham, AL USA

[13] Seattle Genet Inc, Bothell, WA USA

[14] Stanford Canc Inst, Stanford, CA USA

[15] Zymeworks Biopharmaceut Inc, Bothell, WA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期

关键词：

Hodgkin lymphoma; first salvage therapy; autologous stem cell transplantation; brentuximab vedotin; bendamustine; STEM-CELL TRANSPLANTATION; PHASE-II; CHEMOTHERAPY;

D O I：

10.1111/bjh.16499

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E86 / E90

页数：5

共 50 条

[21] BRENTUXIMAB VEDOTIN PLUS VIGEPP CHEMOTHERAPY FOR RELAPSED/REFRACTORY ADOLESCENT HODGKIN LYMPHOMA
Tsaplina, N.
Valiev, T.
LEUKEMIA RESEARCH, 2022, 121 : S60 - S60
[22] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
Chen, Runzhe
Chen, Baoan
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
[23] Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL
Chen, Robert W.
Palmer, Joycelynne
Siddiqi, Tanya
Thomas, Sandra H.
Kim, Young
Binhong, Chen T.
Krishnan, Amrita
Nathwani, Nitya
Cai, Ji-Lian
Mott, Michelle
Matsuoka, Deron
Forman, Stephen J.
BLOOD, 2012, 120 (21)
[24] Brentuximab Vedotin and Bendamustine Combination Therapy as Salvage for Relapsed-Refractory Hodgkin Lymphoma: A Real-World Single-Center Experience
Bajaj, Rajat
Radhakrishnan, Vivek
Bhave, Saurabh
Kumar, Jeevan
Arora, Neeraj
Dey, Debdeep
Parihar, Mayur
Mishra, Deepak
Chandy, Mammen
Nair, Reena
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S246 - S247
[25] SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE
Tsirigotis, P.
Vassilakopoulos, T.
Bousiou, Z.
Mpatsis, I.
Gkirkas, K.
Sakellari, I.
Papageorgiou, S.
Roussou, P.
Pangalis, G.
Galani, Z.
Moschoyianni, M.
Vassilopoulos, G.
Repoussis, P.
Megalakaki, E.
Michalis, E.
Anagnostopoulos, N.
Calpadaki, C.
Papadaki, H.
Margaritis, D.
Chatzimichail, E.
Briassoulis, E.
Spyridonidis, A.
Grentzelias, D.
Anargyrou, K.
Tsionos, K.
Mpanti, A.
Poulakidas, E.
Palaska, C.
Gribabi, D.
Apostolidis, J.
Pappa, V.
Harhalakis, N.
Panayiotidis, P.
Konstantopoulos, K.
Anagnostopoulos, A.
Angelopoulou, M.
HAEMATOLOGICA, 2015, 100 : 454 - 455
[26] Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis
Forlenza, Christopher J.
Gulati, Nitya
Mauguen, Audrey
Absalon, Michael J.
Castellino, Sharon M.
Franklin, Anna
Keller, Frank G.
Shukla, Neal
BLOOD, 2020, 136
[27] Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
Vinti, Luciana
Pagliara, Daria
Buffardi, Salvatore
Di Ruscio, Valentina
Stocchi, Francesca
Mariggio, Elena
Parasole, Rosanna
Di Matteo, Antonia
Petruzziello, Fara
Paganelli, Valeria
De Vito, Rita
Del Bufalo, Francesca
Strocchio, Luisa
Locatelli, Franco
PEDIATRIC BLOOD & CANCER, 2022, 69 (04)
[28] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
Kambhampati, Swetha
Mei, Matthew
Chen, Lu
Puverel, Sandrine
Chen, Robert
Popplewell, Leslie L.
Nikolaenko, Liana
Peters, Lacolle
Armenian, Saro H.
Kwak, Larry W.
Rosen, Steve T.
Forman, Stephen J.
Herrera, Alex F.
BLOOD, 2022, 140 : 9418 - 9419
[29] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Salihoglu, A.
Elverdi, T.
Karadogan, I.
Paydas, S.
Ozdemir, E.
Erdem, G.
Karadurmus, N.
Akyol, G.
Kaynar, L.
Yegin, Z. A.
Sucak, G.
Ozkocaman, V.
Topcuoglu, P.
Ozcan, M.
Birtas, E.
Goker, H.
Baslar, Z.
Ferhanoglu, B.
ANNALS OF HEMATOLOGY, 2015, 94 (03) : 415 - 420
[30] Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
Siddiqi, Tanya
Thomas, Sandra H.
Chen, Robert
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 79 - 85

← 1 2 3 4 5 →